Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.
How this was made
The 30-second read
Why it matters
The Phase 1 data provide the first human safety and PK readout for the topical formulation, a key milestone before advancing to pivotal trials.
Market read
First‑time disclosure of Phase 1 results could move DARE stock as investors reassess the FSAD pipeline.
What to watch
Funding needs for later‑stage trials and competition from other FSAD candidates.
Background
Daré Bioscience (NASDAQ: DARE) focuses on women’s sexual health and is developing a topical sildenafil cream for female sexual arousal disorder (FSAD).
Ticker impact
Daré Bioscience presented Phase 1 sildenafil cream safety and bioavailability data at the SMSNA meeting.
likely upward pressure as market prices in the favorable safety and PK profile.
The study showed dramatically lower systemic exposure and only mild adverse events, addressing key efficacy and safety concerns for the FSAD program.
Market effects
May boost sentiment for women‑health biotech and topical drug platforms.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
If later trials fail to show efficacy in women, early hype could reverse sharply.
Key entities
- companyDaré Bioscience, Inc.
Biotech developer of the sildenafil cream.
- personAnnie Thurman, MD
Medical Director presenting the data.
